Leinco Technologies

Recombinant Human IL-32α

Product Code:
 
LEI-I-879
Product Group:
 
Recombinant Proteins
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
The lyophilized protein should be stored desiccated at -20°C. The reconstituted protein can be stored for at least one week at 4°C. For long-term storage of the reconstituted protein aliquot into working volumes and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-I-879-10ug10 ug£307.00
Quantity:
LEI-I-879-100ug100 ug£915.00
Quantity:
LEI-I-879-500ug500 ug£4,181.00
Quantity:
LEI-I-879-1mg1 mg£6,906.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
IL-32α is secreted by T cells, natural killer cells, dendritic cells, and keratinocytes.
Long Description:
IL-32 is approximately 26kD and is a pro-inflammatory cytokine that can induce cells of the immune system to secrete inflammatory cytokines including TNFα. IL-32 can also support osteoclast differentiation by regulating the MAPK/ERK pathway and the actin cytoskeleton. IL-32 can exist in at least four differentially spliced isoforms (α, β, γ and δ) with IL-32α being the shortest and most abundant of the four variants. Remarkably, it does not share sequence homology with known cytokine families and is highly expressed in immune tissues. Elevated levels of IL-32 are present in patients with coronary artery disease and endometriosis and may play a role in other autoimmune and inflammatory diseases such as rheumatoid arthritis. In a recent lung cancer study, the inhibitory effects of IL-32γ on tumor development were associated with inhibition of the STAT5 pathway which ultimately demonstrated that IL-32γ negatively regulates tumor development suggesting that IL-32γ has therapeutic potential for use in the treatment of cancer progression.
NCBI Gene:
9235
Purity:
>97% by SDS-PAGE and HPLC
Target:
IL-32 Alpha

References

1. Dahl, CA. et al. (1992) Immunol. 148:5972. Kim, SH. et al. (2005) Immunity 22:1313. Cagnard, N. et al. (2005) Eur. Cyto. Network 16:289